Accessibility Menu
Ligand Pharmaceuticals Stock Quote

Ligand Pharmaceuticals (NASDAQ: LGND)

$184.70
(-0.5%)
-0.88
Price as of October 23, 2025, 12:19 p.m. ET

KEY DATA POINTS

Current Price
$184.7
Daily Change
(-0.5%) $0.88
Day's Range
$183.92 - $186.24
Previous Close
$185.57
Open
$185.46
Beta
1.07
Volume
16,225
Average Volume
221,298
Market Cap
3.6B
Market Cap / Employee
$185.57M
52wk Range
$93.58 - $187.81
Revenue
-
Gross Margin
0.75%
Dividend Yield
N/A
EPS
-$4
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Ligand Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
LGND+74.24%+257.9%+29.05%+539%
S&P+14.5%+93.32%+14.09%+1,381%

Ligand Pharmaceuticals Company Info

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$47.63M14.7%
Gross Profit$36.46M20.1%
Gross Margin76.56%3.4%
Market Cap$2.19B44.9%
Market Cap / Employee$32.26M0.0%
Employees6817.2%
Net Income$4.85M109.3%
EBITDA$18.65M11.4%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$67.67M273.1%
Accounts Receivable$41.29M10.2%
Inventory15.5-25.2%

Liabilities

Q2 2025YOY Change
Long Term Debt$4.63M-27.8%
Short Term Debt$1.11M-4.7%

Ratios

Q2 2025YOY Change
Return On Assets-8.36%-13.5%
Return On Invested Capital2.54%-9.0%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$15.58M21.3%
Operating Free Cash Flow$15.80M19.2%

Valuation

MetricQ4 2023Q1 2024Q2 2024Q3 2024YoY Change
Price to Earnings24.6213.7436.4539.82-
Price to Book2.342.392.422.7547.09%
Price to Sales12.1012.1611.1212.086.11%
Price to Tangible Book Value5.927.687.348.86101.93%
Price to Free Cash Flow TTM24.9621.4539.9742.5626.91%
Enterprise Value to EBITDA79.49163.60-66.38108.6039.95%
Free Cash Flow Yield4.0%4.7%2.5%2.3%-21.21%
Return on Equity6.0%-0.5%-16.6%-9.5%-261.65%
Total Debt$7.36M$7.11M$4.45M$5.74M-24.28%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.